Medical Data Vision Co., Ltd.
Medical Data Vision Co., Ltd. (3902.T) Stock Competitors & Peer Comparison
See (3902.T) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 3902.T | ¥1,684.00 | +0.00% | 63.8B | 227.26 | ¥7.41 | +0.53% |
| 2413.T | ¥1,421.50 | +4.91% | 904.7B | 18.70 | ¥72.49 | +1.62% |
| 4483.T | ¥2,730.00 | +1.56% | 175B | 26.12 | ¥102.41 | +0.67% |
| 2175.T | ¥1,907.00 | +3.59% | 155.5B | 26.74 | ¥70.88 | +1.56% |
| 4480.T | ¥2,260.00 | +4.20% | 62.8B | 68.78 | ¥30.37 | N/A |
| 3733.T | ¥11,230.00 | +0.00% | 59.4B | 9.71 | ¥1,167.92 | +1.41% |
| 2150.T | ¥1,124.00 | +0.00% | 46.6B | 34.48 | ¥32.60 | +1.07% |
| 4820.T | ¥530.00 | -2.57% | 37.8B | 15.46 | ¥35.31 | +7.14% |
| 6078.T | ¥1,391.00 | -1.07% | 37.2B | 59.28 | ¥23.48 | +1.87% |
| 5592.T | ¥2,975.00 | +4.39% | 32B | 10.51 | ¥273.89 | +1.32% |
Stock Comparison
3902.T vs 2413.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 2413.T has a market cap of 904.7B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 2413.T trades at ¥1,421.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 2413.T's P/E ratio is 18.70. In terms of profitability, 3902.T's ROE is +0.10%, compared to 2413.T's ROE of +0.12%. Regarding short-term risk, 3902.T is less volatile compared to 2413.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2413.T's competition here
3902.T vs 4483.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4483.T has a market cap of 175B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4483.T trades at ¥2,730.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4483.T's P/E ratio is 26.12. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4483.T's ROE of +0.08%. Regarding short-term risk, 3902.T is less volatile compared to 4483.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4483.T's competition here
3902.T vs 2175.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 2175.T has a market cap of 155.5B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 2175.T trades at ¥1,907.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 2175.T's P/E ratio is 26.74. In terms of profitability, 3902.T's ROE is +0.10%, compared to 2175.T's ROE of -0.36%. Regarding short-term risk, 3902.T is less volatile compared to 2175.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2175.T's competition here
3902.T vs 4480.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4480.T has a market cap of 62.8B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4480.T trades at ¥2,260.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4480.T's P/E ratio is 68.78. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4480.T's ROE of +0.06%. Regarding short-term risk, 3902.T is less volatile compared to 4480.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4480.T's competition here
3902.T vs 3733.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 3733.T has a market cap of 59.4B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 3733.T trades at ¥11,230.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 3733.T's P/E ratio is 9.71. In terms of profitability, 3902.T's ROE is +0.10%, compared to 3733.T's ROE of +0.14%. Regarding short-term risk, 3902.T is less volatile compared to 3733.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 3733.T's competition here
3902.T vs 2150.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 2150.T has a market cap of 46.6B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 2150.T trades at ¥1,124.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 2150.T's P/E ratio is 34.48. In terms of profitability, 3902.T's ROE is +0.10%, compared to 2150.T's ROE of +0.15%. Regarding short-term risk, 3902.T is less volatile compared to 2150.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2150.T's competition here
3902.T vs 4820.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4820.T has a market cap of 37.8B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4820.T trades at ¥530.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4820.T's P/E ratio is 15.46. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4820.T's ROE of +0.07%. Regarding short-term risk, 3902.T is less volatile compared to 4820.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4820.T's competition here
3902.T vs 6078.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 6078.T has a market cap of 37.2B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 6078.T trades at ¥1,391.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 6078.T's P/E ratio is 59.28. In terms of profitability, 3902.T's ROE is +0.10%, compared to 6078.T's ROE of +0.09%. Regarding short-term risk, 3902.T is less volatile compared to 6078.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 6078.T's competition here
3902.T vs 5592.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 5592.T has a market cap of 32B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 5592.T trades at ¥2,975.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 5592.T's P/E ratio is 10.51. In terms of profitability, 3902.T's ROE is +0.10%, compared to 5592.T's ROE of +0.30%. Regarding short-term risk, 3902.T is less volatile compared to 5592.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 5592.T's competition here
3902.T vs 9438.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 9438.T has a market cap of 31.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 9438.T trades at ¥592.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 9438.T's P/E ratio is 8.91. In terms of profitability, 3902.T's ROE is +0.10%, compared to 9438.T's ROE of +0.19%. Regarding short-term risk, 3902.T is less volatile compared to 9438.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 9438.T's competition here
3902.T vs 4320.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4320.T has a market cap of 28.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4320.T trades at ¥1,653.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4320.T's P/E ratio is 17.20. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4320.T's ROE of +0.20%. Regarding short-term risk, 3902.T is less volatile compared to 4320.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4320.T's competition here
3902.T vs 3939.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 3939.T has a market cap of 24.2B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 3939.T trades at ¥519.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 3939.T's P/E ratio is 21.72. In terms of profitability, 3902.T's ROE is +0.10%, compared to 3939.T's ROE of +0.27%. Regarding short-term risk, 3902.T is less volatile compared to 3939.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 3939.T's competition here
3902.T vs 3649.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 3649.T has a market cap of 18.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 3649.T trades at ¥734.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 3649.T's P/E ratio is 15.00. In terms of profitability, 3902.T's ROE is +0.10%, compared to 3649.T's ROE of +0.22%. Regarding short-term risk, 3902.T is less volatile compared to 3649.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 3649.T's competition here
3902.T vs 5585.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 5585.T has a market cap of 15.8B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 5585.T trades at ¥2,184.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 5585.T's P/E ratio is 58.47. In terms of profitability, 3902.T's ROE is +0.10%, compared to 5585.T's ROE of +0.06%. Regarding short-term risk, 3902.T is less volatile compared to 5585.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 5585.T's competition here
3902.T vs 6095.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 6095.T has a market cap of 15.1B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 6095.T trades at ¥696.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 6095.T's P/E ratio is 8.84. In terms of profitability, 3902.T's ROE is +0.10%, compared to 6095.T's ROE of +0.04%. Regarding short-term risk, 3902.T is less volatile compared to 6095.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 6095.T's competition here
3902.T vs 4263.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4263.T has a market cap of 15B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4263.T trades at ¥908.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4263.T's P/E ratio is -57.99. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4263.T's ROE of -0.11%. Regarding short-term risk, 3902.T is less volatile compared to 4263.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4263.T's competition here
3902.T vs 366A.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 366A.T has a market cap of 13.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 366A.T trades at ¥1,125.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 366A.T's P/E ratio is 14.57. In terms of profitability, 3902.T's ROE is +0.10%, compared to 366A.T's ROE of N/A. Regarding short-term risk, 3902.T is less volatile compared to 366A.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 366A.T's competition here
3902.T vs 9341.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 9341.T has a market cap of 9.7B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 9341.T trades at ¥571.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 9341.T's P/E ratio is 17.14. In terms of profitability, 3902.T's ROE is +0.10%, compared to 9341.T's ROE of +0.04%. Regarding short-term risk, 3902.T is less volatile compared to 9341.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 9341.T's competition here
3902.T vs 2934.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 2934.T has a market cap of 9B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 2934.T trades at ¥1,720.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 2934.T's P/E ratio is -112.68. In terms of profitability, 3902.T's ROE is +0.10%, compared to 2934.T's ROE of +0.03%. Regarding short-term risk, 3902.T is less volatile compared to 2934.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2934.T's competition here
3902.T vs 3671.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 3671.T has a market cap of 7.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 3671.T trades at ¥304.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 3671.T's P/E ratio is 12.74. In terms of profitability, 3902.T's ROE is +0.10%, compared to 3671.T's ROE of +0.15%. Regarding short-term risk, 3902.T is less volatile compared to 3671.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 3671.T's competition here
3902.T vs 3628.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 3628.T has a market cap of 7.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 3628.T trades at ¥649.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 3628.T's P/E ratio is -2.23. In terms of profitability, 3902.T's ROE is +0.10%, compared to 3628.T's ROE of +0.99%. Regarding short-term risk, 3902.T is less volatile compared to 3628.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 3628.T's competition here
3902.T vs 9218.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 9218.T has a market cap of 7.2B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 9218.T trades at ¥707.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 9218.T's P/E ratio is 28.45. In terms of profitability, 3902.T's ROE is +0.10%, compared to 9218.T's ROE of +0.16%. Regarding short-term risk, 3902.T is less volatile compared to 9218.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 9218.T's competition here
3902.T vs 6545.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 6545.T has a market cap of 3.9B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 6545.T trades at ¥746.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 6545.T's P/E ratio is 16.33. In terms of profitability, 3902.T's ROE is +0.10%, compared to 6545.T's ROE of +0.19%. Regarding short-term risk, 3902.T is less volatile compared to 6545.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 6545.T's competition here
3902.T vs 6034.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 6034.T has a market cap of 3.5B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 6034.T trades at ¥620.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 6034.T's P/E ratio is 63.51. In terms of profitability, 3902.T's ROE is +0.10%, compared to 6034.T's ROE of +0.02%. Regarding short-term risk, 3902.T is less volatile compared to 6034.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 6034.T's competition here
3902.T vs 4438.T Comparison May 2026
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 63.8B. In comparison, 4438.T has a market cap of 2.3B. Regarding current trading prices, 3902.T is priced at ¥1,684.00, while 4438.T trades at ¥279.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of 227.26, whereas 4438.T's P/E ratio is -4.32. In terms of profitability, 3902.T's ROE is +0.10%, compared to 4438.T's ROE of -1.49%. Regarding short-term risk, 3902.T is less volatile compared to 4438.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4438.T's competition here